Drug Policy Watch · State Brief 2026

Nevada

Snapshot (structured)

Adult-use cannabis: Legal since 2016 (Question 2), retail sales since July 1, 2017; possession up to 2.5 oz flower / 0.25 oz concentrate as of Jan 1, 2024.
Medical cannabis: Legal since 2000; medical and adult-use retail now merged under a single dual license.
Home grow: Allowed but restricted; up to 6 plants per person / 12 per household only if you live 25+ miles from a licensed dispensary.
Intoxicating hemp / hemp THC: Dispensary-only rule not confirmed. SB 356 (2025), a hemp bill described in some sources as limiting intoxicating hemp products (delta-8, delta-10, THC-O, HHC, high-THC, etc.) to licensed dispensaries, was not enacted: the Legislature recorded no further action allowed on April 12, 2025. AB 504 (2025, Chapter 484) established deceptive trade practices relating to the sale of certain hemp products.
Psychedelics: Not decriminalized; no therapeutic-access program yet. A state psychedelic pilot bill (AB 378, 2025) was not enacted; a working group has recommended a regulated-access framework.
Broad decriminalization: No broad drug decriminalization; standard controlled-substances penalty structure remains.
Harm reduction: Active state programs distribute naloxone and test strips; note fentanyl-test-strip paraphernalia exemption reportedly lapsed Jan 1, 2024 (see Harm reduction section).
Governor (party): Joe Lombardo (Republican).
Legislature control: Democratic majorities in both the Assembly and the Senate (control confirmed for the 2025 session; see Political landscape).
Citizen ballot initiatives allowed: Yes; Nevada permits citizen-initiated statutes and constitutional amendments.
Enclosure pressure score: 4/5

Cannabis

Nevada voters legalized adult-use cannabis through Question 2 in November 2016, with licensed retail sales beginning July 1, 2017. Medical cannabis has been legal since a 2000 constitutional amendment. The independent Cannabis Compliance Board (CCB), created in 2019 under AB 533 and modeled on the state's gaming regulator, licenses and enforces the entire cannabis program, having taken over from the Department of Taxation. Source: https://ccb.nv.gov/ and https://www.mpp.org/states/nevada/

Possession limits were raised by SB 277 (2023, signed by Gov. Lombardo), effective January 1, 2024, to 2.5 ounces of flower and one-quarter ounce of concentrate. Source: https://norml.org/blog/2023/12/27/nevada-new-marijuana-possession-limits-set-to-take-effect/

Home cultivation is permitted but narrowly: a person may grow up to 6 plants (12 per household) only if they reside 25 or more miles from an operating retail dispensary, which excludes most urban residents near Las Vegas and Reno. Source: https://nevadastatecannabis.org/laws and https://www.mpp.org/states/nevada/

Market structure: Nevada uses a dual state-plus-local licensing framework; both CCB approval and local jurisdiction approval are required. Recreational retailers now automatically serve medical patients under a merged "dual license," a change made in the 2025 session. Taxes are a 10% retail excise tax on adult-use sales plus a 15% wholesale excise tax on fair market value at the cultivation-to-production/retail transfer. The market is heavily tied to Las Vegas tourism and features significant multistate operator (MSO) presence; sales have come down from 2021 peaks. Source: https://nevadastatecannabis.org/laws and https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

Consumption lounges: Nevada authorized cannabis consumption lounges (statute enacted 2021), and the CCB has been licensing them, with the first lounges approved and additional lounges (primarily in Las Vegas) advancing. Source: https://www.marijuanamoment.net/nevada-officials-give-final-approval-to-states-first-marijuana-consumption-lounge-set-to-open-this-month/ and https://www.reviewjournal.com/news/politics-and-government/nevada/3-more-marijuana-consumption-lounges-coming-to-nevada-2892180/

Key 2025-2026 actions: The 2025 session (Nevada's legislature is biennial and meets only in odd years) passed roughly seven cannabis-related bills. The fee cuts and the merged dual license date from the 2023 session: SB 277 (2023, Chapter 423, sponsored by Sen. Dallas Harris, approved by the Governor June 14, 2023) lowered the maximum fees the Cannabis Compliance Board may charge to issue or renew most adult-use licenses and deemed each adult-use cannabis establishment a dual licensee (Nevada Legislature, SB 277 (2023)). SB 168 revised packaging, labeling, and single-package THC limits and the definition of usable cannabis. SB 41 tied a cannabis license to obtaining a cannabis tax permit. SB 25 gave the State Fire Marshal inspection authority over production facilities. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/ and https://connorpllc.com/2025-legislative-session-relating-to-cannabis/ and https://legiscan.com/NV/bill/SB168/2025

Hemp

SB 356 (2025), "Revises provisions relating to hemp," sponsored by Sen. Lori Rogich, was not enacted. It was referred to the Senate Committee on Commerce and Labor on March 17, 2025; on April 12, 2025 the Legislature recorded "(Pursuant to Joint Standing Rule No. 14.3.1, no further action allowed.)", and no floor vote was recorded (Nevada Legislature, SB 356). Secondary sources (below) reported a 2025 rule sending intoxicating hemp products (delta-8, delta-10, THC-O, HHC and high-THC items) to licensed cannabis dispensaries only, with potency caps of 10 mg THC per serving and 100 mg per package; the Legislature's record shows that SB 356, the bill this brief tied that rule to, did not become law. AB 504 (2025, Chapter 484, effective October 1, 2025) established deceptive trade practices relating to the sale of, or an offer to sell, certain hemp products. Source: https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/nevada-2025-intoxicating-hemp-dispensary-only and https://burningdaily.com/blogs/learn/nevada-cannabis-hemp-laws

Exposure to federal hemp changes: In November 2025, H.R. 5371 (the Continuing Appropriations and Extensions Act of 2026) closed the federal 2018 Farm Bill "hemp loophole" via Section 781, redefining hemp around a total-THC standard (0.3% total THC including THCA and isomers) and limiting finished consumer products to roughly 0.4 mg total THC per container. These federal changes take effect in two stages, November 12, 2026 for cannabinoids the plant cannot naturally produce and December 11, 2026 for the rest (Section 2019 of H.R. 6500). Source: https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf and https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains

Exposure to the two-stage federal hemp change (November 12 and December 11, 2026) depends on Nevada's existing hemp rules, which this brief has not confirmed: SB 356, the dispensary-only bill described above, was not enacted. How the new federal total-THC definition applies to hemp and CBD products sold in Nevada, including under AB 504, should be treated as unconfirmed pending CCB and Department of Agriculture guidance. Source: https://csgmidwest.org/2026/06/04/farm-bill-loophole-has-led-to-a-booming-industry-for-hemp-derived-products-and-a-mix-of-state-laws-a-new-federal-framework-is-coming-soon/

Psychedelics

Nevada has not decriminalized psilocybin or other psychedelics and has no operating therapeutic-access program. In 2023, SB 242 created a Psychedelic Medicines Working Group housed under the Department of Health and Human Services (a 15-member body) to study psilocybin, psilocin, 5-MeO-DMT, mescaline, and ibogaine for conditions such as PTSD, substance use disorder, and major depressive disorder. The working group issued a December report recommending a state-regulated access program for psychedelic-assisted therapy and reduced penalties. Source: https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group and https://www.marijuanamoment.net/nevada-government-task-force-calls-for-state-regulated-psychedelics-program-and-reduced-penalties/ and https://www.leg.state.nv.us/Division/Research/Documents/RTTL_2023_SB242_2024.pdf

In the 2025 session, AB 378 ("Alternative Therapy Pilot Program," BDR 40-820) would have created a medically supervised pilot allowing veterans and first responders with certain mental health conditions to access psilocybin, DMT, ibogaine, mescaline, and psilocin, overseen by the Division of Public and Behavioral Health. It cleared the Assembly Health and Human Services Committee in April 2025 but was not enacted: it was re-referred to Ways and Means on April 16, 2025, and the Legislature's last entry is "(No further action taken.)" on June 3, 2025, the day the session adjourned sine die (it was not vetoed). Source: https://www.marijuanamoment.net/nevada-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/ and https://thenevadaindependent.com/article/nv-stops-short-of-decriminalizing-magic-mushrooms-some-call-transformative-for-mental-health and https://trackbill.com/bill/nevada-assembly-bill-378-creates-the-alternative-therapy-pilot-program-bdr-40-820/2688912/

2026 bills: None. Nevada's legislature is biennial and does not hold a regular session in 2026; the next chance for a psychedelics bill is the 2027 regular session. The Legislature's record lists Assemblyman Max Carter first among AB 378's sponsors, with Sen. Rochelle Nguyen among its cosponsors. Source: https://lasvegasweekly.com/news/2025/feb/13/nevada-lawmakers-bills-psychedelic-therapy/

Broader drug policy

Decriminalization: Nevada has no broad drug decriminalization. Controlled-substance possession remains subject to the standard penalty structure, though prior reforms reduced some low-level penalties. Source: https://norml.org/laws/nevada-penalties-2/

Harm reduction: State programs are active. Between July 1, 2024 and June 30, 2025, Nevada distributed 56,880 two-dose naloxone units, 108,050 fentanyl test strips, and 58,400 xylazine test strips, and identified three organizations (Roseman, Vitality, Westcare) to run regional mobile harm-reduction units. Naloxone and test strips are available without prescription through local health districts such as the Southern Nevada Health District. However, reporting indicates Nevada's statutory exemption of fentanyl test strips from the drug-paraphernalia definition reverted to prior (non-exempting) language as of January 1, 2024; the current paraphernalia status of test strips should be treated as unconfirmed and worth verifying against statute. Source: https://ag.nv.gov/uploadedFiles/agnvgov/Content/About/Administration/7.9.25%20SURG%20PPT.pdf and https://www.southernnevadahealthdistrict.org/programs/substance-use-and-overdose-prevention/harm-reduction/ and https://nevadacurrent.com/briefs/health-district-reminds-public-free-fentanyl-test-strips-naloxone-are-available/

Sentencing and expungement: Nevada does not offer "expungement" but provides record sealing. AB 192 (2019, the Nevada Second Chance Act, signed by then-Gov. Sisolak, effective July 1, 2019) lets people convicted of marijuana activity that has since been decriminalized or legalized petition the court to seal those records with no filing fee; it is petition-based, not automatic. Source: https://norml.org/news/2019/06/06/nevada-governor-signs-measure-sealing-past-marijuana-convictions/ and https://ccresourcecenter.org/state-restoration-profiles/nevada-restoration-of-rights-pardon-expungement-sealing/

Overdose and treatment policy: The Attorney General's Statewide Substance Use Response Working Group (SURG) coordinates opioid-settlement-funded overdose and treatment strategy and continues to meet (e.g., a July 9, 2025 meeting). Source: https://ag.nv.gov/uploadedFiles/agnvgov/Content/About/Administration/7.9.25%20SURG%20PPT.pdf

Political landscape

Governor: Joe Lombardo (Republican), who signed the 2025 cannabis bills (including SB 277 in 2023 and the 2025 package). Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

Legislature: Democrats hold majorities in both the Assembly and the Senate; the 2025 cannabis package passed with bipartisan support in the Democrat-controlled legislature. Exact 2026 seat counts and any post-2024-cycle changes should be verified, but party control of both chambers by Democrats is well established for the 2025 session. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/ and https://thenevadaindependent.com/article/nevada-policy-tracker-a-quick-guide-to-key-issues-in-the-2025-legislative-session

Key committees: Senate Commerce and Labor (cannabis and hemp commerce bills) and Assembly Health and Human Services (psychedelics and health bills) handled the major 2025 measures. Source: https://archive.leg.state.nv.us/Session/83rd2025/Minutes/Senate/CL/Final/545.pdf and https://archive.leg.state.nv.us/Session/83rd2025/Exhibits/Assembly/HHS/AHHS573P.pdf

Reform champions: On psychedelics, Sen. Rochelle Nguyen and Assemblyman Max Carter are named in reporting as backers of psychedelic-therapy legislation. Source: https://lasvegasweekly.com/news/2025/feb/13/nevada-lawmakers-bills-psychedelic-therapy/ Named opponents of AB 378 are unconfirmed in the sources reviewed.

Ballot initiatives

Nevada permits citizen-initiated ballot measures, including statutory initiatives and constitutional amendments (constitutional amendments by initiative must pass at two consecutive general elections). Cannabis itself was legalized via the 2016 citizen initiative Question 2. Source: https://www.mpp.org/states/nevada/ and https://www.leg.state.nv.us/

No pending statewide cannabis, psychedelic, or drug-policy citizen ballot measure for 2026 was identified in the sources reviewed; treat the existence of any 2026 measure as unconfirmed/none-found. Reform energy in this cycle has run through the legislature and the executive working group rather than the ballot. Source: https://thenevadaindependent.com/article/nevada-policy-tracker-a-quick-guide-to-key-issues-in-the-2025-legislative-session

Equity and expungement

Social equity: Nevada's cannabis statutes and CCB rules do not center a robust social-equity licensing program comparable to some other states; the 2025 reforms were oriented toward reducing operator fees and penalties rather than expanding equity ownership. Specific social-equity license set-asides are not documented in the sources reviewed and should be treated as unconfirmed. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/ and https://ccb.nv.gov/

Expungement/record sealing: Nevada uses petition-based record sealing, not automatic expungement. AB 192 (2019) lets people with now-decriminalized or legalized marijuana convictions petition to seal those records without a fee. Because relief is petition-based, it benefits those who know about and pursue the process and effectively excludes those who do not file; there is no automatic statewide sealing mechanism. Source: https://norml.org/news/2019/06/06/nevada-governor-signs-measure-sealing-past-marijuana-convictions/ and https://ccresourcecenter.org/state-restoration-profiles/nevada-restoration-of-rights-pardon-expungement-sealing/

Market and barriers

Taxes: 10% adult-use retail excise tax plus 15% wholesale excise tax on fair market value at transfer. Source: https://nevadastatecannabis.org/laws

License fees: SB 277 (2023, Chapter 423) lowered the maximum fees the CCB may charge to issue or renew most adult-use licenses (Nevada Legislature, SB 277 (2023)); specific current fee schedules are set by the CCB. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

License caps and counts: Nevada caps retail licenses (historically allocated by county/population) and requires dual state-plus-local approval, with significant MSO presence. Exact current license caps and the precise number of active licensees are set and published by the CCB and are not stated with a hard number in the sources reviewed; treat specific counts as unconfirmed pending CCB data. Source: https://ccb.nv.gov/ and https://nevadastatecannabis.org/laws

Capital/residency requirements: Specific capital minimums and any residency requirements are governed by CCB licensing rules and are not quantified in the sources reviewed; treat as unconfirmed. Source: https://ccb.nv.gov/laws-regulations/

Enclosure read

Who is being fenced out: small operators and new entrants face a capped, dual-approval, vertically capable, MSO-heavy market; home growers are largely excluded by the 25-mile rule (most urban residents cannot legally grow). SB 356 (2025), the bill this brief had credited with moving intoxicating hemp out of convenience stores and gas stations and into dispensaries, was not enacted; the two-stage federal hemp redefinition (November 12 and December 11, 2026) bears directly on small hemp sellers. Who is consolidating: incumbent licensed cannabis operators and MSOs, who gained fee relief and the merged dual license in 2023 (SB 277).

Justification for score 4/5: The market is licensed, capped, and dual-approval gated; home grow is effectively off-limits to most residents; and there is no broad decriminalization, no social-equity license program documented, and only petition-based (non-automatic) record sealing. It is not a 5 because cannabis is fully legal with a functioning consumer market, consumption lounges are opening, harm-reduction distribution is active, and the citizen-initiative path remains available. Net: heavily fenced with some open edges, hence 4/5. Note (October 27, 2026): this justification previously included "intoxicating hemp has been routed to incumbent dispensaries," which rested on SB 356 (2025). SB 356 was not enacted. The 4/5 score has not been re-examined without that element; that review is scheduled for November 10, 2026.

What to watch next

November 12 and December 11, 2026: federal hemp redefinition takes effect in two stages (Section 2019 of H.R. 6500), including the 0.3 percent total-THC standard and the separate 0.4 mg per container cap; watch for CCB and Department of Agriculture guidance on how the new federal definition applies to hemp products sold in Nevada. Source: https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf
February 2027: next regular biennial legislative session convenes; expect renewed psychedelic-therapy legislation (post-AB 378) and possible follow-on cannabis/hemp bills. Source: https://www.leg.state.nv.us/
Psychedelic Medicines Working Group recommendations remain the template for a future regulated-access bill. Source: https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group
Consumption lounge rollout in Las Vegas (additional CCB approvals). Source: https://www.reviewjournal.com/news/politics-and-government/nevada/3-more-marijuana-consumption-lounges-coming-to-nevada-2892180/
CCB rulemaking implementing the 2025 statutory changes (fees, labeling, hemp). Source: https://ccb.nv.gov/laws-regulations/

Regulators

Cannabis Compliance Board (CCB): licenses and enforces all medical and adult-use cannabis, including consumption lounges. https://ccb.nv.gov/
Nevada Department of Health and Human Services (DHHS) / Division of Public and Behavioral Health: houses the Psychedelic Medicines Working Group and would have administered the proposed psychedelic pilot; oversees behavioral health and overdose programs. https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group
Nevada Department of Agriculture: historically regulates the hemp program/registration (current scope not confirmed here). https://agri.nv.gov/
Office of the Attorney General / Statewide Substance Use Response Working Group (SURG): coordinates opioid-settlement and overdose/treatment strategy. https://ag.nv.gov/
Local jurisdictions (e.g., Clark County, City of Las Vegas, Washoe County): co-approve cannabis establishments under the dual licensing framework.

Federal exposure (2026)

Rescheduling and 280E: Cannabis remains Schedule I by federal default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027. Because Nevada runs both an adult-use and a medical program, the split matters: the state's medical cannabis category gains relief from IRC Section 280E (the provision that bars normal business deductions for sellers of Schedule I/II substances), while the adult-use side, which is the dominant revenue channel tied to Las Vegas tourism, does not. Nevada's 2025 merger of medical and adult-use retail into a single "dual license" blurs that line operationally, but the federal tax treatment turns on the substance's schedule and the medical-versus-recreational character of the sale, not the state license type, so most Nevada dispensary revenue stays under 280E and stays Schedule I. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state recreational businesses. Source: https://www.marijuanamoment.net/

The November 12 and December 11, 2026 hemp cliff: The federal hemp redefinition now lands in two stages: November 12, 2026 for products containing cannabinoids the cannabis plant cannot naturally produce, and December 11, 2026 for the rest of Section 781, including the 0.3 percent total-THC standard and the 0.4 mg per container cap (Section 2019 of H.R. 6500, signed September 2, 2026). FDA missed the February 10, 2026 deadline to publish the cannabinoid lists that determine which products fall on which date, so the status of converted cannabinoids such as delta-8 is unsettled. A two-year delay bill, H.R. 7024, has not advanced. How exposed Nevada is depends on state hemp rules this brief has not confirmed: SB 356 (2025), which this brief had described as routing intoxicating hemp out of convenience stores and gas stations and into licensed dispensaries only, was not enacted (the Legislature recorded no further action allowed on April 12, 2025). How the federal total-THC definition (including THCA and isomers) and the 0.4 mg per container cap apply to hemp and CBD products sold in Nevada should be treated as unconfirmed pending CCB and Department of Agriculture guidance. Source: https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf and https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains

Banking: SAFER Banking has stalled in a Republican Congress. Nevada cannabis operators, including the MSOs that dominate the market, remain cut off from normal banking, card payments, and federal lending, which raises the cost of capital and reinforces incumbent advantage (those with existing banking relationships and scale absorb cash-handling and compliance costs that price out small entrants). Source: https://www.marijuanamoment.net/

Psychedelics: Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but there is no federal approval yet. In Nevada the 2025 pilot bill (AB 378) was not enacted and the SB 242 (2023) Psychedelic Medicines Working Group recommended a state-regulated access framework, but with no 2026 session the earliest state vehicle is 2027. A purely state therapeutic-access program (the working group template) would run into the same federal Schedule I wall that has constrained other states; the cleaner near-term federal pathway for Nevadans is FDA approval of a specific psychedelic medicine, which would convert that single substance to a prescribable Schedule III-style product without requiring state legislation. Source: https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group and https://www.marijuanamoment.net/

Fentanyl: The HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I, hardening the federal penalty backdrop against which Nevada's standard controlled-substances structure operates; Nevada has no broad decriminalization to cushion this.

Harm reduction: Nevada is directly exposed to the SAMHSA guidance of April 24, 2026 that bars federal funds for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone. Nevada's active distribution program (in the most recent year, 108,050 fentanyl test strips, 58,400 xylazine test strips, and clean-supply distribution alongside 56,880 naloxone units) leans on federal and opioid-settlement money; the federal cut threatens the test-strip and syringe components specifically, leaving naloxone as the protected line item. This compounds Nevada's existing ambiguity over whether fentanyl test strips are exempt from the state paraphernalia definition (reportedly reverted January 1, 2024, treated as unconfirmed above). Source: https://www.southernnevadahealthdistrict.org/programs/substance-use-and-overdose-prevention/harm-reduction/ and https://ag.nv.gov/uploadedFiles/agnvgov/Content/About/Administration/7.9.25%20SURG%20PPT.pdf

Patient access and rights

This section covers what Nevada law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Nevada has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Nevada is not among them. The absence is the finding: a Nevada patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Nevada protects a patient in one of the six areas, employment. NRS Section 678C.850 requires an employer to attempt a reasonable accommodation for a patient's medical cannabis use, unless it would threaten harm, impose undue hardship, or keep the employee from fulfilling their job (subsections (2) and (3)). A review of Chapter 678C found no protection for housing, parenting, an organ transplant list, or school enrollment, and the medical-care provision (subsection (1)) only declines to require insurers to cover cannabis. Those gaps are the finding.

Out-of-state patients: Nevada offers full reciprocity; under NRS 678C.470 it recognizes a valid nonresident medical card.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Nevada has not enacted a Ryan's Law. The broader protections above are a creature of Nevada law, not federal law.

Sources: Nevada patient protections, NRS Chapter 678C, Section 678C.850.

Analysis: the enclosure read in depth

Who is fenced out in Nevada: small operators and new entrants confront a market that is capped, vertically capable, MSO-heavy, and gated by dual state-plus-local approval (both CCB and the relevant county or city must sign off), so a single jurisdiction can foreclose entry even where state law would allow it. Home growers are excluded by the 25-mile rule, which is a near-total home-grow ban for urban Nevada: the overwhelming majority of the population lives in metro Las Vegas (Clark County) and Reno (Washoe County) within 25 miles of an operating dispensary, so legal personal cultivation is realistically available only to rural residents. SB 356 (2025), which this brief had described as removing the low-barrier intoxicating-hemp path that convenience stores, gas stations, and smoke shops used, was not enacted. The result is that the would-be craft growers and home cultivators who could most cheaply enter are systematically routed out; whether state law also fences out independent hemp retailers is not confirmed here.

Who consolidates: incumbent licensed cannabis operators and MSOs. The 2023 session handed them fee cuts and caps and a merged dual retail/medical license that lets a single licensee serve both customer bases (SB 277). They are the parties positioned to absorb cash-only banking costs, dual-approval friction, and compliance overhead.

State-plus-federal interaction: the federal layer mostly reinforces the state enclosure rather than cutting against it. The two-stage federal hemp cliff (November 12 and December 11, 2026) cuts off the interstate gray-market supply that small sellers relied on; stalled SAFER Banking keeps capital scarce in a way that favors scaled incumbents; continued Schedule I status for recreational cannabis keeps 280E on the dominant revenue line, which again rewards operators with the accounting sophistication and margin to manage it; and the medicalize-and-control federal posture (medical-only Schedule III relief, FDA-gated psychedelics) channels future openings toward large, capitalized, FDA-capable incumbents rather than community or small-scale actors. Non-intoxicating CBD is a likely friction point: the stricter federal total-THC container cap could catch products now sold in Nevada, which is unconfirmed.

What to watch: CCB and Department of Agriculture guidance on how the federal total-THC definition applies to hemp products sold in Nevada before the two-stage federal hemp cliff (November 12 and December 11, 2026); whether the DEA rescheduling hearing produces anything beyond the medical-only Schedule III move (and whether it slips to 2027); the fate of Nevada's harm-reduction test-strip and syringe funding under the April 2026 SAMHSA bar; and the February 2027 session as the next and only near-term vehicle for a psychedelic-access bill or any home-grow or social-equity expansion.

Where commons counter-moves are limited: Nevada's biennial legislature holds no regular 2026 session, so the legislative channel is closed until February 2027, removing the fastest counter-lever for two years. The citizen-initiative path remains formally open (cannabis itself came via Question 2 in 2016), but it is slow and, for a constitutional amendment, requires passage at two consecutive general elections. There is no documented social-equity licensing program to widen ownership, record relief is petition-based rather than automatic, and the executive working group on psychedelics can only recommend, not enact. So the practical commons responses, namely legislation, equity carve-outs, and home cultivation, are each either time-locked, absent, or narrowly drawn.

Justification for the enclosure score (4/5): the market is licensed, capped, dual-approval gated, and MSO-dominated; home grow is off-limits to nearly all urban residents; banking scarcity and 280E favor scale; there is no broad decriminalization, no documented social-equity program, only petition-based sealing, and no 2026 legislative session to push back. It is not a 5 because cannabis is fully legal with a functioning consumer market, consumption lounges are opening, harm-reduction distribution is active (for now), and the citizen-initiative path remains available. Heavily fenced with a few open edges, hence 4/5. Note (October 27, 2026): this justification previously included "intoxicating hemp has been routed to incumbent dispensaries," which rested on SB 356 (2025). SB 356 was not enacted. The 4/5 score has not been re-examined without that element; that review is scheduled for November 10, 2026.

Active legislation (2026)

Nevada's legislature is biennial and meets in regular session only in odd-numbered years. There is no regular legislative session in 2026 and therefore no active 2026 drug-policy bills; the items below are significant 2025 (83rd Session) measures and their outcomes, including bills that were not enacted. The next regular session convenes in February 2027.

Bill	Title/Topic	Chamber	Status	Sponsor(s)
SB 356 (2025)	Revises provisions relating to hemp; reported as a dispensary-only rule for intoxicating hemp (not enacted)	Senate	Not enacted. Referred to Senate Commerce and Labor March 17, 2025; last recorded action: (Pursuant to Joint Standing Rule No. 14.3.1, no further action allowed.), April 12, 2025. No floor vote recorded; the 83rd Session adjourned sine die June 3, 2025	Sen. Lori Rogich (sponsor of record)
AB 504 (2025)	Deceptive-trade-practice provisions for unlicensed hemp sellers	Assembly	Enacted	unconfirmed
SB 168 (2025)	Cannabis packaging/labeling, usable cannabis definition, single-package THC limits	Senate	Enacted	unconfirmed
SB 41 (2025)	Requires cannabis tax permit tied to license	Senate	Enacted	unconfirmed
SB 25 (2025)	State Fire Marshal inspection authority over cannabis production facilities	Senate	Enacted	unconfirmed
AB 378 (2025)	Alternative Therapy (psychedelics) Pilot Program for veterans/first responders	Assembly	Not enacted. Reported from Assembly Health and Human Services with a do-pass-as-amended recommendation April 15, 2025; re-referred to Ways and Means April 16, 2025; last recorded action: (No further action taken.), June 3, 2025, the day the session adjourned sine die	Asm. Max Carter (listed first); cosponsors include Asms. Gray, D'Silva, A. Hansen, Brown-May and Sens. I. Hansen, Nguyen and Stone

This list is not exhaustive. For the full long tail and any 2027 prefiled measures, use the live trackers: LegiScan Nevada (https://legiscan.com/NV), the Nevada Legislature site (https://www.leg.state.nv.us/), and Marijuana Moment's bill tracker (https://www.marijuanamoment.net/). Source: https://connorpllc.com/2025-legislative-session-relating-to-cannabis/ and https://legiscan.com/NV/bill/SB168/2025 and https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most. Gifts are not tax-deductible.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common.